Clay Siegall’s Seattle Genetics Paves The Way For Targeted Cancer Treatment

As a scientist, Clay Siegall has spent his life dedicated to research. After receiving his undergraduate degree from the University of Maryland in Zoology and his Ph.D. from George Washington University in Genetics, he began working for numerous scientific organizations. His employers included the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institute of Health, and the National Cancer Institute.

 

 

In 1998, Dr. Siegall decided to venture out on his own. He founded Seattle Genetics, a scientific research company that was created by his passion for helping patients. The company’s emphasis would be placed on targeted cancer therapies, with Dr. Siegall as its President, CEO, and Chairman of the Board. Seattle Genetics uses scientific research, innovation and drug development as its guide to providing a better life for cancer patients.

 

 

Under his leadership, Seattle Genetics has become a leader and pioneer within the industry, focused on created ADCs, or antibody-drug conjugates. They received their first FDA approval in 2011 for their first ADC, ADCETRIS. This ADC is made in collaboration with Takeda Pharmaceutical Company, becoming a global brand with approvals in over 60 countries. Since ADCETRIS’ FDA approval, Seattle Genetics has begun developing a pipeline of proprietary ADCs to help treat cancer and improve the lives of cancer patients.

 

 

Clay Siegall’s guidance has led Seattle Genetics into numerous strategic licenses regarding their innovative ADC technology. These licenses involved prestigious companies like Pfizer, AbbVie, GlaxoSmithKline, and Genentech, resulting in a generation of funding equaling $325 million. These partnerships have also allowed for the ability to begin developing more than 20 ADCs. These ADCs have all entered the clinical stages of development and would not have been possible without the innovative ADC technology created by Seattle Genetics.

 

 

  1. Siegall has led the way in his company’s capital-raising endeavors, aiding Seattle Genetics in acquiring more than $1.2 billion through private and public funding. He serves in many other endeavors that include having a seat on the Board of Directors at places like Ultragenyx Pharamaceutical, the Washington Roundtable, and Alder BioPharmaceuticals. His is a highly awarded scientist, receiving the 2013 University of Maryland Alumnus of the Year award, and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year award.